November 24, 2023 – Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday Biotech Sale: 12 Stocks for XBI-MAS." Despite overall market health, biotech stocks have significantly declined, with the XBI biotech index 56% lower than its 5-year high, and 30% of NASDAQ-listed biotech companies trading at negative enterprise value.
Stonegate believes biotech stocks, having underperformed, could outperform broader markets despite an expected market reset. After evaluating 2,251 publicly traded biotech companies and screening 266 NASDAQ-listed companies, Stonegate's selection criteria yielded a shopping list of 12 interesting companies in the top 1% based on institutional support with robust pipelines, upcoming milestones, and strong management teams.
The top three companies on the shopping list are aTyr Pharma, Rezolute (NasdaqCM:RZLT), and Vincerx Pharma. The full report is attached to this release for download.
At Stonegate Healthcare Partners our mission is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development and Investor Outreach. The firm's research approach is centered on comprehensive and comparative analyses in specific healthcare fields. We aim to identify programs with high synergy to our strategic understanding of the space and technologies with the highest disruptive potential. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, enabling a current understanding of unmet need and emerging disruptive technologies.
